Verve Therapeutics Inc（VERV）资讯与事件VERVVerve Therapeutics Inc

Eli Lilly completes acquisition of Verve Therapeutics

Eli Lilly and Company (LLY) announced the successful completion of its acquisition of Verve Therapeutics. (VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

Eli Lilly and Verve Therapeutics announce expiration of Verve tender offer

Eli Lilly (LLY) and Verve Therapeutics (VERV) announced that the tender offer to purchase all of the issued and outstanding shares of Verve's common stock in exchange for $10.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus one non-tradable contingent value right per Share, which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of a certain specified milestone, expired on July 23 and was not extended. 49,882,464 Shares were validly tendered and not validly withdrawn in the Offer, representing approximately 55.7% of the issued and outstanding Shares as of the Expiration Time. Accordingly, all conditions to the offer have been satisfied. Lilly and Ridgeway Acquisition Corporation, an indirect wholly owned subsidiary of Lilly, have accepted for payment, and will promptly pay for, all shares validly tendered and not validly withdrawn in the offer. The parties expect to consummate the acquisition on July 25, 2025, in accordance with, and subject to the terms of, the definitive agreement for the proposed acquisition.

JonesResearch lists factors for Prime Medicine continued share rally

JonesResearch says Prime Medicine (PRME) continues to rally following the management change on May 19, rallying $160% since mid-June. Verve Therapeutics' (VERV) acquisition by Eli Lilly for $1.3B, a "large price/valuation discrepancy," insider share buying and a higher short interest are factors behind the stock's momentum, the analyst tells investors in a research note. Jones believes initial clinical data will be essential for Prime to be a real takeover target. While gene editing is considered more suitable for severe diseases with acute unmet need, Lilly's acquisition shows that there is an appetite for gene editing in larger market diseases, the firm contends. Jones sees Prime as a "prime candidate for acquisition," but says it is unlikely to happen without clinical data from the company's Wilson disease or alpha-1 antitrypsin deficiency programs, which will be in 2027. It keeps a Buy rating on Prime Medicine with a $5 price target. The stock in midday trading is up 32%, or $1.00, to $4.11.